EMOOLA SINGAPORE PTE. LTD.

Business Description

EMOOLA SINGAPORE PTE. LTD. is registered as a business entity on 01 January 2017 (8.3 years ago) structured as a Exempt Private Company Limited By Shares (Local Company) with 3 officer(s) in-charge. The business jurisdiction is overseen by the Accounting and Corporate Regulatory Authority (ACRA), a government agency from Singapore with the given Business Registration Number / Unique Entity Number (UEN) 201700036M. The business official address is located at 101 Upper Cross Street #05-40a, People's Park Centre, Singapore 58357 with main trading activity as E-commerce And It Services Etc in the primary industry of 62011: Development Of Software And Applications (except Games And Cybersecurity) using Singapore Dollars - SGD as its default trading currency. The business legal name has undergone change(s) and is previously known as DDBILL INTERNATIONAL SINGAPORE PTE. LTD.. The business annual account filing date falls on 31 July and is currently operational with the status of 'Live Company'. The business paid up share capital is USD 1,000,000, with preference share capital of USD 0, and other share capital at USD 0.

In the past 365 days, EMOOLA SINGAPORE PTE. LTD. has received a total of Login to view reported payment review(s). 5 were rated Good and Login to view were rated Poor. The latest review was made on 2023-06-10 and it was reported "Good". The aggregated good payment amount is equivalent to USD 3,130, and aggregated poor payment amount is equivalent to USD Login to view. Its current payment rating of "A" suggest a healthy payment culture where settlement with stakeholders is always prioritised. Since the business is currently active, it also signals positive financial standing. The lack of an appointed auditor indicates that the business is small sized as it did not meet the regulatory requirements of revenue or assets exceeding SGD 10 million, or has more than 50 employees in the previous two fiscal years.

EMOOLA SINGAPORE PTE. LTD. is not yet a Prompt Payment Initiative Signatory.

Last updated on 30 April 2023